eResearchTechnology senkt EPS-Erwartungen - 500 Beiträge pro Seite | Diskussion im Forum
eröffnet am 01.10.04 14:01:12 von
neuester Beitrag 22.03.05 17:54:42 von
neuester Beitrag 22.03.05 17:54:42 von
Beiträge: 7
ID: 910.053
ID: 910.053
Aufrufe heute: 0
Gesamt: 394
Gesamt: 394
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 07:23 | 1619 | |
| vor 1 Stunde | 1324 | |
| vor 1 Stunde | 843 | |
| vor 1 Stunde | 611 | |
| 02.05.24, 18:44 | 562 | |
| 01.05.24, 18:36 | 493 | |
| heute 06:53 | 465 | |
| gestern 21:04 | 430 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.235,02 | +0,10 | 288 | |||
| 2. | 2. | 10,380 | -1,89 | 77 | |||
| 3. | 4. | 1,1200 | -12,50 | 76 | |||
| 4. | 3. | 172,04 | +0,26 | 66 | |||
| 5. | 5. | 86,05 | -0,75 | 36 | |||
| 6. | 6. | 7,0340 | +1,65 | 34 | |||
| 7. | 7. | 19,264 | +0,28 | 33 | |||
| 8. | 14. | 18,900 | -0,79 | 30 |
FeedbackDemnach geht das Unternehmen nun von einem Gewinn je Aktie zwischen 13 und 14 Cents aus, nachdem es zuvor
Die Aktie von eResearchTechnology notiert in New York vorbörslich mit einem Plus von 2,78 Prozent bei 13,70 Dollar.
Wertpapiere des Artikels:
ERESEARCHTECHNOLOGY, INC.
Autor: SmartHouseMedia (© wallstreet:online AG / SmartHouse Media GmbH),13:55 01.10.2004
hätte nie gedacht,dass ich ERES nochmals unter 12 Dollar kaufen kann...diese Aktie wird sich wieder erholen,da lege ich die Hand ins Feuer!!!
eResearchTechnology, Inc. Updates Third Quarter and Full Year Outlook
Friday October 1, 7:00 am ET
PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES - News), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, updated its outlook for the third quarter ended September 30, 2004 and year ending December 31, 2004.
eRT expects revenue in the third quarter to grow between 55% and 60% year over year with revenues between $27.0 million and $28.0 million and earnings per diluted share to grow between 85% and 100% year over year to $0.13 to $0.14, compared to the company`s previous guidance of $30.0 million to $30.5 million in revenues and earnings per diluted share of $0.16 to $0.17. The company expects revenues for the full year to grow between 68% and 72% year over year with revenues between $112.0 million and $115.0 million and earnings per diluted share to grow between 115% and 122% year over year to $0.58 to $0.60, compared to company`s previous guidance of $117.0 million to $119.0 million in revenues and earnings per diluted share of $0.62 to $0.63.
The third quarter results were impacted by delays in Thorough Phase I studies, with a transaction value of approximately $3.0 million, due to weather, inadequate patient enrollment and late stage protocol amendments consistent with regulatory guidance updates. eRT anticipates that these studies will be completed in the fourth quarter. In addition, targeted one- time technology sales were not consummated by end of the third quarter as the company had anticipated. The company`s fourth quarter and year-end outlook reflect the impact of delays in receiving three new Thorough Phase I signings in the third quarter that the company had previously anticipated. The combination of a historically slower period for new signings, in addition to sponsor review of recent updates to regulatory guidance, likely contributed to these signing delays, which the company will target to consummate in the fourth quarter.
The company plans to announce complete third quarter results on October 20, 2004 and will provide additional information regarding 2004 and 2005 guidance at that time. These adjustments are based on a preliminary review of eRT`s results of operations for the quarter ended September 30, 2004.
The company will host a conference call to discuss this announcement. The conference call will take place at 8:45 a.m. EDT on October 1, 2004. Interested participants should call 888-874-9713 when calling within the United States or 973-935-8506 when calling internationally. There will be a playback available until October 15, 2004. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 5245597 for the replay.
This call is being webcast by ViaVid Broadcasting and can be accessed at eRT`s web site at http://www.eRT.com. The webcast may also be accessed at ViaVid`s website at http://www.viavid.net/detailpage.aspx?sid=00001F19 . The webcast can be accessed until October 15, 2004 on either site.
eResearchTechnology, Inc. Updates Third Quarter and Full Year Outlook
Friday October 1, 7:00 am ET
PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES - News), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, updated its outlook for the third quarter ended September 30, 2004 and year ending December 31, 2004.
eRT expects revenue in the third quarter to grow between 55% and 60% year over year with revenues between $27.0 million and $28.0 million and earnings per diluted share to grow between 85% and 100% year over year to $0.13 to $0.14, compared to the company`s previous guidance of $30.0 million to $30.5 million in revenues and earnings per diluted share of $0.16 to $0.17. The company expects revenues for the full year to grow between 68% and 72% year over year with revenues between $112.0 million and $115.0 million and earnings per diluted share to grow between 115% and 122% year over year to $0.58 to $0.60, compared to company`s previous guidance of $117.0 million to $119.0 million in revenues and earnings per diluted share of $0.62 to $0.63.
The third quarter results were impacted by delays in Thorough Phase I studies, with a transaction value of approximately $3.0 million, due to weather, inadequate patient enrollment and late stage protocol amendments consistent with regulatory guidance updates. eRT anticipates that these studies will be completed in the fourth quarter. In addition, targeted one- time technology sales were not consummated by end of the third quarter as the company had anticipated. The company`s fourth quarter and year-end outlook reflect the impact of delays in receiving three new Thorough Phase I signings in the third quarter that the company had previously anticipated. The combination of a historically slower period for new signings, in addition to sponsor review of recent updates to regulatory guidance, likely contributed to these signing delays, which the company will target to consummate in the fourth quarter.
The company plans to announce complete third quarter results on October 20, 2004 and will provide additional information regarding 2004 and 2005 guidance at that time. These adjustments are based on a preliminary review of eRT`s results of operations for the quarter ended September 30, 2004.
The company will host a conference call to discuss this announcement. The conference call will take place at 8:45 a.m. EDT on October 1, 2004. Interested participants should call 888-874-9713 when calling within the United States or 973-935-8506 when calling internationally. There will be a playback available until October 15, 2004. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 5245597 for the replay.
This call is being webcast by ViaVid Broadcasting and can be accessed at eRT`s web site at http://www.eRT.com. The webcast may also be accessed at ViaVid`s website at http://www.viavid.net/detailpage.aspx?sid=00001F19 . The webcast can be accessed until October 15, 2004 on either site.
Press Release Source: eResearchTechnology, Inc.
eResearchTechnology, Inc. to Announce Third Quarter Results on October 20, 2004
Wednesday October 13, 9:21 am ET
PHILADELPHIA, Oct. 13 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) (Nasdaq: ERES - News), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it will release its third quarter results for the period ended September 30, 2004 on Wednesday, October 20, 2004 after the market closes. After the release, the company will host a conference call to discuss these results.
ADVERTISEMENT
The conference call will take place at 4:45 PM EDT later that day. Interested participants should call 888-874-9713 when calling within the United States or 973-935-8506 when calling internationally. There will be a playback available as well. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 5265677 for the replay.
This call is being webcast by ViaVid Broadcasting and can be accessed at eRT`s web site at http://www.eRT.com. The webcast may also be accessed at ViaVid`s website at: http://www.viavid.net/detailpage.aspx?sid=00001F40. The webcast can be accessed until November 20, 2004 on either site.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company`s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company`s financial results can be found in the company`s Reports on Form 10-K filed with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: eResearchTechnology, Inc.
jethor
eResearchTechnology, Inc. to Announce Third Quarter Results on October 20, 2004
Wednesday October 13, 9:21 am ET
PHILADELPHIA, Oct. 13 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) (Nasdaq: ERES - News), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it will release its third quarter results for the period ended September 30, 2004 on Wednesday, October 20, 2004 after the market closes. After the release, the company will host a conference call to discuss these results.
ADVERTISEMENT
The conference call will take place at 4:45 PM EDT later that day. Interested participants should call 888-874-9713 when calling within the United States or 973-935-8506 when calling internationally. There will be a playback available as well. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 5265677 for the replay.
This call is being webcast by ViaVid Broadcasting and can be accessed at eRT`s web site at http://www.eRT.com. The webcast may also be accessed at ViaVid`s website at: http://www.viavid.net/detailpage.aspx?sid=00001F40. The webcast can be accessed until November 20, 2004 on either site.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company`s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company`s financial results can be found in the company`s Reports on Form 10-K filed with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: eResearchTechnology, Inc.
jethor
Hoffe, dass Du recht hast.
ERES liefert brilliante Zahlen - ist aber auch extrem hoch bewertet - priced for perfection eben.
Jede Abweichung wird sich somit bitter rächen. Das Potenzial muss daher als Riskoprämie ordentlich sein.
Bin jetzt auch wieder mit einer kleineren Position drin.
ERES liefert brilliante Zahlen - ist aber auch extrem hoch bewertet - priced for perfection eben.
Jede Abweichung wird sich somit bitter rächen. Das Potenzial muss daher als Riskoprämie ordentlich sein.
Bin jetzt auch wieder mit einer kleineren Position drin.
Quote & News Charts Financials Analysts Options SEC Filings
TRACK THESE TOPICS
My Portfolio Alerts
Company: Eresearchtechnology Inc Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
The stock (ERES: news, chart, profile) fell $2.94 to $10.65 in after-hours action.
The provider of technology and services to biotechnology and medical device firms now expects to post 2004 earnings within a range of 52 cents a share to 56 cents a share, down from its earlier estimate of a range between 58 cents a share and 60 cents a share. The average estimate of analysts polled by Thomson First Call had been 58 cents a share.
Among other factors, eResearchTechnology blamed the revision on increased costs related to semi-automated processing, increased sales and marketing expenditures, and the impact of a higher tax rate.
EResearchTechnology said its third-quarter profit rose to $7.4 million, or 13 cents a share, from $3.9 million, or 7 cents a share, in the same quarter last year. Revenue rose 60 percent to $17.5 million. Respondents to First Call`s survey were expecting a profit of 14 cents a share on revenue of $27.3 million.
The company also issued a forecast for the fourth quarter of this year, saying it expects to earn 11 cents to 15 cents a share on revenue between $26 million and $30 million. Analysts had anticipated a profit of 16 cents a share on $31.5 million in revenue.
In 2005, eResearchTechnology expects to earn 62 cents to 72 cents a share on revenue of $130 million to $140 million. The First Call targets were a profit of 78 cents a share on $155.9 million in
jethor
TRACK THESE TOPICS
My Portfolio Alerts
Company: Eresearchtechnology Inc Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
The stock (ERES: news, chart, profile) fell $2.94 to $10.65 in after-hours action.
The provider of technology and services to biotechnology and medical device firms now expects to post 2004 earnings within a range of 52 cents a share to 56 cents a share, down from its earlier estimate of a range between 58 cents a share and 60 cents a share. The average estimate of analysts polled by Thomson First Call had been 58 cents a share.
Among other factors, eResearchTechnology blamed the revision on increased costs related to semi-automated processing, increased sales and marketing expenditures, and the impact of a higher tax rate.
EResearchTechnology said its third-quarter profit rose to $7.4 million, or 13 cents a share, from $3.9 million, or 7 cents a share, in the same quarter last year. Revenue rose 60 percent to $17.5 million. Respondents to First Call`s survey were expecting a profit of 14 cents a share on revenue of $27.3 million.
The company also issued a forecast for the fourth quarter of this year, saying it expects to earn 11 cents to 15 cents a share on revenue between $26 million and $30 million. Analysts had anticipated a profit of 16 cents a share on $31.5 million in revenue.
In 2005, eResearchTechnology expects to earn 62 cents to 72 cents a share on revenue of $130 million to $140 million. The First Call targets were a profit of 78 cents a share on $155.9 million in
jethor
Trading Spotlight
lobale Suche nach bestgeführten Firmen /
Lux Topic - Best Managed Firms Fund investiert in US-amerikanische IT- und Biotechwerte
22.03.2005 - 11:15 Uhr, PeopleInvest Pressemappe [Pressemappe]
München (ots) - Die Fondsstrategie von PeopleInvest, nur in
exzellent geführte Unternehmen zu investieren, funktioniert auch
global: Der im April 2004 aufgelegte Investmentfonds Lux Topic - Best
Managed Firms Fund (WKN A0BLYJ) hat das Portfolio um drei
US-Wachstumswerte aus den Sektoren Informations- und Biotechnologie
erweitert. Der Fokus des Fonds wird dennoch weiter auf europäischen
Small und Mid Caps mit hervorragendem Management liegen. "In den
Sektoren IT und Biotech sitzen die besten Manager in den USA. Um auch
diese Potenziale für den Best Managed Firms Fund zu nutzen, haben wir
uns in den USA nach lohnenden Investments umgesehen", so Arnaud
Mende, Gründer und geschäftsführender Gesellschafter von
PeopleInvest.
Nach Gesprächen vor Ort und einer professionellen
Managementbewertung entschied sich PeopleInvest für SanDisk
Corporation, Curis und eResearch Technology. Die Unternehmen zeichnen
sich durch überzeugende Wachstumsstories und herausragende Qualität
des Managements aus. Die SanDisk Corporation, Weltmarktführer bei
Flash-Speicherchips, profitiert vom boomenden Massenmarkt der
digitalen Endgeräte. PeopleInvest überzeugt die innovative Stärke des
Unternehmens, die sich bisher in 350 Patenten niederschlug. Das
Management verbindet diese Innovationskraft mit außergewöhnlichem
Marketingtalent, was sich bei der professionellen Steuerung der
Vertriebskanäle zeigt.
Das Biotechnologie-Unternehmen Curis entwickelt Medikamente zur
regenerativen Behandlung von Krebs, Nierenversagen,
Herz-Kreislauferkrankungen und Haarausfall. Das Management verfolgt
einen strikt risikoaversen Ansatz in einem Wachstumsmarkt. Für
PeopleInvest stellt das Managementteam um CEO Daniel Passeri eine
ideale Kombination aus unternehmerischen und wissenschaftlichen
Fähigkeiten dar.
Das Medizintechnikunternehmen eResearch Technology ist Marktführer
für Produkte und Dienstleistungen zur digitalen Datenübertragung von
Krankheitsbildern - einem Wachstumsmarkt insbesondere in den USA. Das
Management um CEO Joseph Esposito bringt klinische Kenntnisse,
Expertise in der Softwareentwicklung und unternehmerischen
Fähigkeiten zusammen.
Für den Best Managed Firms Fund bedeuten die drei neuen
Technologiewerte eine stärkere Gewichtung der Wachstumswerte in einem
Portfolio, das bisher einen Schwerpunkt auf Value Aktien legte. Die
Stichhaltigkeit der Fondsstrategie zeigt sich in der bisherigen
Wertentwicklung des Fonds, der mit einer Performance von 12,22
Prozent nach sechs Monaten den Vergleichsindex MSCI World weit hinter
sich lässt.
Pressekontakt
Pleon Kohtes Klewes GmbH
Juliane Kanzler
juliane.kanzler@pleon.com
089/59042-222
ots, obs, ogs und ors (ORIGINALTEXTSERVICE, ORIGINALBILDSERVICE, ORIGINALGRAFIKSERVICE, ORIGINALRADIOSERVICE) sind Dienste der news aktuell GmbH, © 2005 news aktuell GmbH, alle Rechte vorbehalten. Diese Inhalte dienen ausschließlich zur redaktionellen Nutzung und zur individuellen Information des Nutzers. Eine Speicherung in Datenbanken sowie jegliche Weitergabe an Dritte im Rahmen gewerblicher Nutzung oder zur gewerblichen Nutzung sind nur mit schriftlicher Genehmigung durch news aktuell GmbH gestattet. news aktuell haftet nicht bei Fehlern oder Störungen im Dienstbetrieb, bei Lieferschwierigkeiten, inhaltlichen oder textlichen Fehlern, außer in Fällen groben Verschuldens. Im übrigen gelten unsere AGB. Für den Fall, daß Sie die Inhalte der news aktuell GmbH weitergeben, speichern oder gewerblich nutzen möchten, bieten wir Ihnen an, Content-Partner zu werden.
news aktuell GmbH FON +49 (0)40 4113 2850 Kontakt Impressum Sitemap
jethor
Lux Topic - Best Managed Firms Fund investiert in US-amerikanische IT- und Biotechwerte
22.03.2005 - 11:15 Uhr, PeopleInvest Pressemappe [Pressemappe]
München (ots) - Die Fondsstrategie von PeopleInvest, nur in
exzellent geführte Unternehmen zu investieren, funktioniert auch
global: Der im April 2004 aufgelegte Investmentfonds Lux Topic - Best
Managed Firms Fund (WKN A0BLYJ) hat das Portfolio um drei
US-Wachstumswerte aus den Sektoren Informations- und Biotechnologie
erweitert. Der Fokus des Fonds wird dennoch weiter auf europäischen
Small und Mid Caps mit hervorragendem Management liegen. "In den
Sektoren IT und Biotech sitzen die besten Manager in den USA. Um auch
diese Potenziale für den Best Managed Firms Fund zu nutzen, haben wir
uns in den USA nach lohnenden Investments umgesehen", so Arnaud
Mende, Gründer und geschäftsführender Gesellschafter von
PeopleInvest.
Nach Gesprächen vor Ort und einer professionellen
Managementbewertung entschied sich PeopleInvest für SanDisk
Corporation, Curis und eResearch Technology. Die Unternehmen zeichnen
sich durch überzeugende Wachstumsstories und herausragende Qualität
des Managements aus. Die SanDisk Corporation, Weltmarktführer bei
Flash-Speicherchips, profitiert vom boomenden Massenmarkt der
digitalen Endgeräte. PeopleInvest überzeugt die innovative Stärke des
Unternehmens, die sich bisher in 350 Patenten niederschlug. Das
Management verbindet diese Innovationskraft mit außergewöhnlichem
Marketingtalent, was sich bei der professionellen Steuerung der
Vertriebskanäle zeigt.
Das Biotechnologie-Unternehmen Curis entwickelt Medikamente zur
regenerativen Behandlung von Krebs, Nierenversagen,
Herz-Kreislauferkrankungen und Haarausfall. Das Management verfolgt
einen strikt risikoaversen Ansatz in einem Wachstumsmarkt. Für
PeopleInvest stellt das Managementteam um CEO Daniel Passeri eine
ideale Kombination aus unternehmerischen und wissenschaftlichen
Fähigkeiten dar.
Das Medizintechnikunternehmen eResearch Technology ist Marktführer
für Produkte und Dienstleistungen zur digitalen Datenübertragung von
Krankheitsbildern - einem Wachstumsmarkt insbesondere in den USA. Das
Management um CEO Joseph Esposito bringt klinische Kenntnisse,
Expertise in der Softwareentwicklung und unternehmerischen
Fähigkeiten zusammen.
Für den Best Managed Firms Fund bedeuten die drei neuen
Technologiewerte eine stärkere Gewichtung der Wachstumswerte in einem
Portfolio, das bisher einen Schwerpunkt auf Value Aktien legte. Die
Stichhaltigkeit der Fondsstrategie zeigt sich in der bisherigen
Wertentwicklung des Fonds, der mit einer Performance von 12,22
Prozent nach sechs Monaten den Vergleichsindex MSCI World weit hinter
sich lässt.
Pressekontakt
Pleon Kohtes Klewes GmbH
Juliane Kanzler
juliane.kanzler@pleon.com
089/59042-222
ots, obs, ogs und ors (ORIGINALTEXTSERVICE, ORIGINALBILDSERVICE, ORIGINALGRAFIKSERVICE, ORIGINALRADIOSERVICE) sind Dienste der news aktuell GmbH, © 2005 news aktuell GmbH, alle Rechte vorbehalten. Diese Inhalte dienen ausschließlich zur redaktionellen Nutzung und zur individuellen Information des Nutzers. Eine Speicherung in Datenbanken sowie jegliche Weitergabe an Dritte im Rahmen gewerblicher Nutzung oder zur gewerblichen Nutzung sind nur mit schriftlicher Genehmigung durch news aktuell GmbH gestattet. news aktuell haftet nicht bei Fehlern oder Störungen im Dienstbetrieb, bei Lieferschwierigkeiten, inhaltlichen oder textlichen Fehlern, außer in Fällen groben Verschuldens. Im übrigen gelten unsere AGB. Für den Fall, daß Sie die Inhalte der news aktuell GmbH weitergeben, speichern oder gewerblich nutzen möchten, bieten wir Ihnen an, Content-Partner zu werden.
news aktuell GmbH FON +49 (0)40 4113 2850 Kontakt Impressum Sitemap
jethor
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 288 | ||
| 77 | ||
| 76 | ||
| 66 | ||
| 36 | ||
| 34 | ||
| 33 | ||
| 30 | ||
| 28 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 23 | ||
| 21 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 17 | ||
| 16 | ||
| 16 | ||
| 15 |
